首页> 美国卫生研究院文献>OncoTargets and therapy >A Phase Ib study of ruxolitinib + gemcitabine ± nab-paclitaxel in patients with advanced solid tumors

【2h】

A Phase Ib study of ruxolitinib + gemcitabine ± nab-paclitaxel in patients with advanced solid tumors

机译：鲁索替尼+吉西他滨±纳布-紫杉醇治疗晚期实体瘤的Ib期研究

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
引文网络
相似文献
相关主题

摘要

PurposeAberrant activation of the Janus-associated kinase (JAK)/signal transducer and activator of transcription (STAT) pathway is associated with increased malignant cell proliferation and survival. This Phase Ib study evaluated ruxolitinib, a potent JAK1/2 inhibitor, in combination with gemcitabine with or without nab-paclitaxel in patients with advanced solid tumors.

机译：目的Janus相关激酶（JAK）/信号转导子和转录激活子（STAT）通路的异常激活与恶性细胞增殖和存活增加有关。这项Ib期研究评估了晚期实体瘤患者中有效的JAK1 / 2抑制剂ruxolitinib联合吉西他滨联合或不联合nab-紫杉醇的疗效。

著录项

期刊名称 OncoTargets and therapy
作者
Todd M Bauer; Manish R Patel; Andres Forero-Torres; Thomas J George Jr; Albert Assad; Yining Du; Herbert Hurwitz;
展开▼
作者单位

展开▼
年(卷),期 2018(11),-1
年度 2018
页码 2399–2407
总页数 9
原文格式 PDF
正文语种
中图分类应用微生物学;肿瘤学;
关键词
Janus kinase inhibitor pancreatic cancer;

机译：Janus激酶抑制剂;胰腺癌;

相似文献

外文文献
中文文献
专利

1. A Phase Ib study of ruxolitinib + gemcitabine ± nab-paclitaxel in patients with advanced solid tumors [J] . Todd M Bauer, Manish R Patel, Andres Forero-Torres, OncoTargets and therapy . 2018,第1期

机译：鲁索替尼+吉西他滨±纳布-紫杉醇治疗晚期实体瘤的Ib期研究
2. A Phase Ib/II Study of the JAK1 Inhibitor, Itacitinib, plus nab-Paclitaxel and Gemcitabine in Advanced Solid Tumors [J] . Beatty Gregory L., Shahda Safi, Beck Thaddeus, The oncologist . 2019,第1期

机译：JAK1抑制剂，Itacitinib，纳布 - 紫杉醇和吉西他滨的A相IB / II研究在先进的实体瘤中
3. Phase Ib study of dovitinib in combination with gemcitabine plus cisplatin or gemcitabine plus carboplatin in patients with advanced solid tumors [J] . GalskyM.D., PosnerM., HolcombeR.F., Cancer chemotherapy and pharmacology. . 2014,第3期

机译：多维替尼联合吉西他滨联合顺铂或吉西他滨联合卡铂在晚期实体瘤患者中的Ib期研究
4. Phase I Clinical Trial with Her-2 B-Cell Chimeric and MultiEpitope Based Peptide Vaccines in Patients with Metastatic and/or Recurrent Solid Tumors [C] . Pravin T.P. Kaumaya, Kevin Chu Foy, Joan Garrett American Peptide Symposium . 2009

机译：患者临床试验与患有转移和/或复发性固体瘤的患者的HER-2 B细胞嵌合和多型肽疫苗
5. A phase I study of vincristine, escalating doses of irinotecan, temozolomide and bevacizumab (VIT-B) in pediatric and adolescent patients with recurrent or refractory solid tumors of non-hematopoietic origin [D] . Venkatramani, Rajkumar. 2010

机译：长春新碱，伊非替康，替莫唑胺和贝伐单抗（VIT-B）逐步剂量在患有非造血源性复发或难治性实体瘤的儿童和青少年患者中的I期研究
6. Phase Ib study of dovitinib in combination with gemcitabine plus cisplatin or gemcitabine plus carboplatin in patients with advanced solid tumors [O] . Matthew D. Galsky, Marshall Posner, Randall F Holcombe, -1

机译：多维替尼联合吉西他滨联合顺铂或吉西他滨联合卡铂在晚期实体瘤患者中的Ib期研究
7. Phase Ib study of dovitinib in combination with gemcitabine plus cisplatin or gemcitabine plus carboplatin in patients with advanced solid tumors [O] . Matthew D. Galsky, Marshall Posner, Randall F. Holcombe, 2014

机译：Dovitinib与Gemcitabine Plus顺铂或Gemcitabine Plus Carboplatin联合治疗高级实体肿瘤

A Phase Ib study of ruxolitinib + gemcitabine ± nab-paclitaxel in patients with advanced solid tumors

摘要

著录项

引文网络

相似文献

相关主题

期刊订阅